<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1202">
  <stage>Registered</stage>
  <submitdate>21/06/2006</submitdate>
  <approvaldate>28/06/2006</approvaldate>
  <actrnumber>ACTRN12606000261516</actrnumber>
  <trial_identification>
    <studytitle>LACE  Laparoscopic Approach to Cancer of the Endometrium: An International Multicenter Randomized Phase 3 Clinical Trial</studytitle>
    <scientifictitle>LACE - Laparoscopic Approach to Cancer of the Endometrium: An International Multicenter Randomized Phase 3 Clinical Trial. The primary objective is to assess disease free survival 4.5 years post-operatively.</scientifictitle>
    <utrn />
    <trialacronym>LACE</trialacronym>
    <secondaryid>ClinicalTrials.gov: NCT00096408</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Endometrial Adenocarcinoma - FIGO Stage 1</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Womb (Uterine or endometrial cancer)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Total Abdominal Hysterectomy (TAH) + pelvic/aortic lymph node dissection.
Total Laparoscopic Hysterectomy (TLH) + laparoscopic pelvic/aortic lymph node dissection</interventions>
    <comparator>Total Abdominal Hysterectomy (TAH) + pelvic aortic lymph node dissection.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: surgery</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Disease-free survival</outcome>
      <timepoint>4.5 years after surgery</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Intra/Peri/Post-operative and long-term morbidity</outcome>
      <timepoint>12 months after surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Patterns of recurrence</outcome>
      <timepoint>4.5 years after surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment Costs.</outcome>
      <timepoint>4 weeks to 12 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of Life.</outcome>
      <timepoint>Preoperatively and 4.5 years postoperative.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pelvic Floor Functioning.</outcome>
      <timepoint>Preoperatively and 4.5 years postoperative.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Survival.</outcome>
      <timepoint>At 4.5 years follow-up.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients who may be included for this study must have the following:Histologically confirmed primary endometrioid adenocarcinoma of the endometrium; Clinical stage I disease; ECOG Performance status of 0-1; Signed written informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients will be excluded from participating from the study if they have any of the following:Other histologic type than endometrioid adenocarcinoma of the endometrium; Clinically advanced disease (stages II-IV); Uterine size larger than 10 weeks gestation; Estimated life expectancy of less than 6 months; Enlarged aortic lymph nodes; Unfit for Surgery: serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator); Patient compliance and geographic proximity that does not allow adequate follow-up; Unfit to complete QoL measurements.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation is not  concealed</concealment>
    <sequence>Randomised permuted blocks will be used to allocate patients between the two treatment groups with an allocation ratio of 2:1, favouring the intervention of TLH (variable blocks sizes). Randomisations will be stratified according to treating centre and by grade of differentiation (as taken from the endometrial biopsy/D&amp;C).</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/10/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>755</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC,QLD,SA,WA</recruitmentstate>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Pokfulam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Edinburgh</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Edinburgh</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Qld Centre for Gynaecological Cancer</primarysponsorname>
    <primarysponsoraddress>Level 6, Ned Hanlon Building
Royal Brisbane and Womens Hospital
Herston QLD 4029</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Qld Cancer Fund</fundingname>
      <fundingaddress>PO Box 201, Spring Hill Qld 4004</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Cancer Council (NSW, WA, VIC)</fundingname>
      <fundingaddress>153 Dowling Street 
Woolloomooloo, NSW 2011
PO Box 572
Kings Cross NSW 1340
Australia</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Tyco</fundingname>
      <fundingaddress>2nd Floor, 90 Pitts Bay Road
Pembroke HM 08, Bermuda
United States</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Johnson &amp; Johnson</fundingname>
      <fundingaddress>Not available</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Genentech</fundingname>
      <fundingaddress>Genentech, Inc.
1 DNA Way
South San Francisco, CA 94080-4990</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>NHMRC</fundingname>
      <fundingaddress>National Health and Medical Research Council
GPO Box 1421
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>QUEENSLAND HEALTH</fundingname>
      <fundingaddress>Queensland Health Building
147-163 Charlotte Street
Brisbane Queensland 4000</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Cancer Australia</fundingname>
      <fundingaddress>PO Box 1201,
Dickson, Canberra ACT 2602</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Cancer Australia</fundingname>
      <fundingaddress>PO Box 1201,
Dickson, Canberra ACT 2602</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>University of Queensland</sponsorname>
      <sponsoraddress>The University of Queensland
Brisbane QLD 4072 Australia</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Phase 3

This study compares standard abdominal surgery with laparoscopic (keyhole) surgery for women with early stage cancer of the endometrium (lining of the womb).

Who is it for?
You can join this study if you have early stage cancer of the endometrium (lining of the womb) that has not spread beyond the wall of the womb. This is determined by scans before the operation.

Trial details
Participants will be randomly divided into two groups. One group receives standard abdominal surgery and the other receives laparoscopic (keyhole) surgery for removing the uterus (womb). Women will have an equal chance of being offered one or other surgical approaches and will be followed for up to 4 Â½ years to trace any women whose cancers return.

Normally, surgery is carried out through a cut just above the pelvic bone, and the womb is removed together with ovaries and fallopian tubes. Lymph nodes may also have to be removed. For almost all women, this is curative surgery.

This new technique may reduce some of the problems that people may experience immediately after surgery and in the longer term. The study is seeking to understand whether the same excellent outcomes can be achieved with surgery that is usually better tolerated.</summary>
    <trialwebsite>delete web site, no longer valid</trialwebsite>
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Brisbane and Women's Hospital</ethicname>
      <ethicaddress>Herston, Qld</ethicaddress>
      <ethicapprovaldate>20/09/2004</ethicapprovaldate>
      <hrec>2004/025</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Mater Health Services</ethicname>
      <ethicaddress>South Brisbane Qld</ethicaddress>
      <ethicapprovaldate>26/11/2004</ethicapprovaldate>
      <hrec>777P</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Greenslopes Private Hospital</ethicname>
      <ethicaddress>Greenslopes Qld</ethicaddress>
      <ethicapprovaldate>14/12/2004</ethicapprovaldate>
      <hrec> 04/12</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Wesley Hospital</ethicname>
      <ethicaddress>Auchenflower, Qld</ethicaddress>
      <ethicapprovaldate>25/08/2005</ethicapprovaldate>
      <hrec>2004/60</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Monash Medical Centre</ethicname>
      <ethicaddress>East Bentleigh, Vic</ethicaddress>
      <ethicapprovaldate>18/11/2004</ethicapprovaldate>
      <hrec>04144C</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St John of God Hopsital</ethicname>
      <ethicaddress>Subiaco WA </ethicaddress>
      <ethicapprovaldate>2/06/2005</ethicapprovaldate>
      <hrec>213</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>King Edward Memorial Hospital</ethicname>
      <ethicaddress>Subiaco, WA</ethicaddress>
      <ethicapprovaldate>5/07/2005</ethicapprovaldate>
      <hrec>EC05-42.3</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Westmead Hospital</ethicname>
      <ethicaddress>Westmead, NSW</ethicaddress>
      <ethicapprovaldate>30/03/2006</ethicapprovaldate>
      <hrec>2006/12/4.27</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>The Townsville Health Service District Institutional Ethics Committee</ethicname>
      <ethicaddress>PO Box 670 TOWNSVILLE QLD 4810</ethicaddress>
      <ethicapprovaldate>5/10/2006</ethicapprovaldate>
      <hrec>55/06</hrec>
      <ethicsubmitdate>21/09/2006</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Mater Misericordiae Hospital Townsville Research &amp; Ethics Committee</ethicname>
      <ethicaddress>Locked Bag 1000 TOWNSVILLE DC QLD 4810</ethicaddress>
      <ethicapprovaldate>17/07/2007</ethicapprovaldate>
      <hrec>NA</hrec>
      <ethicsubmitdate>23/05/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>The Royal Women's Hospital Human Ethics Committee</ethicname>
      <ethicaddress>The Royal Women's Hospital 132 Grattan Street CARLTON VIC 3053</ethicaddress>
      <ethicapprovaldate>24/10/2006</ethicapprovaldate>
      <hrec>06/30</hrec>
      <ethicsubmitdate>6/06/2006</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Cabrini Hospital Human Research Ethics Committee</ethicname>
      <ethicaddress>183 Wattletree Road MALVERN VIC 3144</ethicaddress>
      <ethicapprovaldate>21/08/2006</ethicapprovaldate>
      <hrec>01-21-08-06</hrec>
      <ethicsubmitdate>1/08/2006</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Hunter New England Human Research Ethics Committee</ethicname>
      <ethicaddress>Locked Bag 1 Lookout Road NEW LAMBTON NSW 2305</ethicaddress>
      <ethicapprovaldate>3/04/2007</ethicapprovaldate>
      <hrec>07/03/21/3.04</hrec>
      <ethicsubmitdate>23/03/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital Research Ethics Committee</ethicname>
      <ethicaddress>Royal Adelaide Hospital Research Ethics Committee Level 3, Hanson Institute North Terrace ADELAIDE SA 5000</ethicaddress>
      <ethicapprovaldate>4/05/2007</ethicapprovaldate>
      <hrec>070413</hrec>
      <ethicsubmitdate>6/03/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Upper B South Regional Ethics Committee</ethicname>
      <ethicaddress>Ministry of Health
4th Floor, 250 Oxford Terrace
PO Box 3877
Christchurch New Zealand</ethicaddress>
      <ethicapprovaldate>21/07/2006</ethicapprovaldate>
      <hrec>URB/06/06/049</hrec>
      <ethicsubmitdate>1/07/2006</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Institutional Review Board of the University of Hong Kong</ethicname>
      <ethicaddress>Hong Kong West Cluster,
Queen Mary Hospital,
102 Pokfulam Road
Pokfulam Hong Kong</ethicaddress>
      <ethicapprovaldate />
      <hrec>New ethics HREC. Please modify.</hrec>
      <ethicsubmitdate>1/02/2008</ethicsubmitdate>
      <ethiccountry>Hong Kong</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Andreas Obermair</name>
      <address>QCGC
Teaching and Research Level 6
Ned Hanlon Building
Royal Brisbane and Women's Hospital
Herston  Qld  4026</address>
      <phone>+61 7 3636 5485</phone>
      <fax>+61 7 3636 2307</fax>
      <email>andreas_obermair@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ms Trudi Cattley</name>
      <address>QCGC
Teaching and Research Level 6
Ned Hanlon Building
Royal Brisbane and Women's Hospital
Herston  Qld  4026</address>
      <phone>+61 7 3636 0447</phone>
      <fax>+61 7 3636 1721</fax>
      <email>trudi_cattley@helath.qld.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Trudi Cattley</name>
      <address>QCGC Teaching and Research Level 6 Ned Hanlon Building Royal Brisbane and Women's Hospital Herston Qld 4026</address>
      <phone>+61 7 3636 5486</phone>
      <fax>+61 7 3636 1721</fax>
      <email>trudi_cattley@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>